Liminatus Pharma, Inc.
LIMN
$0.14
$0.013.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 700.90K | 884.20K | 701.20K | 1.12M | 264.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.10M | 884.20K | 701.20K | 1.12M | 264.20K |
| Operating Income | -1.10M | -884.20K | -701.20K | -1.12M | -264.20K |
| Income Before Tax | -1.12M | -8.17M | -1.82M | 113.30K | -327.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.12M | -8.17M | -1.82M | 113.30K | -327.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.12M | -8.17M | -1.82M | 113.30K | -327.50K |
| EBIT | -1.10M | -884.20K | -701.20K | -1.12M | -264.20K |
| EBITDA | -1.10M | -883.70K | -700.60K | -1.12M | -- |
| EPS Basic | -0.03 | -0.30 | -0.07 | 0.00 | -0.02 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.06 | -0.03 | -0.01 |
| EPS Diluted | -0.03 | -0.30 | -0.07 | 0.00 | -0.02 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.06 | -0.03 | -0.01 |
| Average Basic Shares Outstanding | 36.00M | 27.10M | 27.01M | 23.30M | 17.50M |
| Average Diluted Shares Outstanding | 36.00M | 27.10M | 27.01M | 23.30M | 17.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |